Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of the Oral Administration of ASP8273 in Patients With Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

NCT02192697 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02192697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02192697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of the Oral Administration of ASP8273 in Patients With Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
January 23, 2014
Completion date
June 14, 2017
Enrollment
124 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer